PT  - JOURNAL ARTICLE
AU  - Tan, C. Sabrina
AU  - Collier, Ai-ris Y.
AU  - Liu, Jinyan
AU  - Yu, Jingyou
AU  - Chandrashekar, Abishek
AU  - McMahan, Katherine
AU  - Wan, Huahua
AU  - He, Xuan
AU  - Jacob-Dolan, Catherine
AU  - Sellers, Daniel
AU  - Ventura, John D.
AU  - Bartsch, Yannic
AU  - Hauser, Blake M.
AU  - Munt, Jennifer E.
AU  - Mattocks, Melissa
AU  - Stephenson, Kathryn E.
AU  - Vidal, Samuel J.
AU  - Jaegle, Kate
AU  - Rowe, Marjorie
AU  - Hemond, Rachel
AU  - Rivera, Lorraine Bermudez
AU  - Anioke, Tochi
AU  - Barrett, Julia
AU  - Chung, Benjamin
AU  - Gardner, Sarah
AU  - Gebre, Makda S.
AU  - Hachmann, Nicole
AU  - Lifton, Michelle
AU  - Miller, Jessica
AU  - Nampanya, Felix
AU  - Powers, Olivia
AU  - Sciacca, Michaela
AU  - Siamatu, Mazuba
AU  - Surve, Nehalee
AU  - Tostanoski, Lisa H.
AU  - VanWyk, Haley
AU  - Wu, Cindy
AU  - Baric, Ralph S.
AU  - Schmidt, Aaron G.
AU  - Alter, Galit
AU  - Barouch, Dan H.
TI  - Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant
AID  - 10.1101/2021.12.02.21267198
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.02.21267198
4099  - http://medrxiv.org/content/early/2021/12/30/2021.12.02.21267198.short
4100  - http://medrxiv.org/content/early/2021/12/30/2021.12.02.21267198.full
AB  - The rapid spread of the highly mutated SARS-CoV-2 Omicron variant has raised substantial concerns about the protective efficacy of currently available vaccines. We assessed Omicron-specific humoral and cellular immune responses in 65 individuals who were vaccinated with two immunizations of BNT162b2 and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24) (Table S1).Competing Interest StatementDHB is a co-inventor on provisional vaccine patents (63/121,482; 63/133,969; 63/135,182). The authors report no other conflict of interest.Clinical TrialNCT04999111Funding StatementThe authors acknowledge Janssen Vaccines & Prevention, NIH grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation (D.H.B.). The authors also acknowledge the Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health & Human Development and Burroughs Wellcome Fund HD000849 (A.Y.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BIDMC institutional review board approved this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptThe datasets generated during and/or analysed during the current study and the analysis codes used to produce the figures and tables are available in the Open Science Framework repository, https://doi.org/10.17605/OSF.IO/HQNKR. https://doi.org/10.17605/OSF.IO/HQNKR.